Champions OncologyCSBR -0.98%64 PB Ratio is 19.74 as of Jun. 25, 2026, which is 13% below its 10-year median of 22.61. GuruFocus rates CSBR with a GF Score™ of 64/100 and a GF Value™ of $6.62 (Fairly Valued). The stock has 2 warning signs investors should review. Among 1,233 Biotechnology companies, Champions Oncology ranks worse than 93.51% on this metric.
Champions Oncology Inc stock PB Ratio (=19.94) is close to 3-year low of 18.34.
The historical rank and industry rank for Champions Oncology's PB Ratio or its related term are showing as below:
CSBR'
s PB Ratio Range Over the Past 10 Years
Min: 5.1 Med: 22.61 Max: 958.57
Current: 19.61
During the past 13 years, Champions Oncology's highest PB Ratio was 958.57. The lowest was 5.10. And the median was 22.61.
CSBR's PB Ratio is ranked worse than 93.51% of 1233
companies
in the Biotechnology industry
Industry Median: 2.8
vs CSBR: 19.61
During the past 12 months, Champions Oncology's average Book Value Per Share Growth Rate was -22.80% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -25.90% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Champions Oncology was 334.40% per year. The lowest was -82.50% per year. And the median was 9.05% per year.
Back to Basics: PB Ratio
Champions Oncology (NAS:CSBR) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Champions Oncology PB Ratio Related Terms
Champions Oncology PB Ratio Historical Data
* Premium members only.
The historical data trend for Champions Oncology's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Champions Oncology's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Champions Oncology PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Champions Oncology's PB Ratio distribution charts can be found below:
* The bar in red indicates where Champions Oncology's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Champions Oncology (CSBR) has a PB Ratio of 19.74 as of Jun. 25, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Champions Oncology and its competitors. This is 13% below median its historical median of 22.61. Over the past decade, Champions Oncology's PB Ratio has ranged from 5.10 to 958.57. According to the industry distribution chart, Champions Oncology ranks #1153 out of 1233 companies in the Biotechnology industry, placing it in the top 93.5%.
Is Champions Oncology's PB Ratio too high?
Champions Oncology's current PB Ratio of 19.74 is 13% below median its 10-year median of 22.61. Over the past 10 years, this metric has ranged from a low of 5.10 to a high of 958.57. The Biotechnology industry median PB Ratio is 2.80. Champions Oncology's value of 19.74 is 605% above this industry median. Based on the distribution chart, Champions Oncology ranks #1153 out of 1233 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Champions Oncology has a GF Score™ of 64/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Champions Oncology's PB Ratio compare to ANVS and HYFT?
According to the Biotechnology industry distribution chart, Champions Oncology ranks #1153 out of 1233 companies for PB Ratio. This places Champions Oncology in the lower half of its industry. The industry median PB Ratio is 2.80. Champions Oncology's value of 19.74 is 605% above this benchmark. Historically, Champions Oncology's own PB Ratio has ranged from 5.10 to 958.57 over the past decade. While the company's 10-year median is 22.61 vs. the industry median of 2.80, Champions Oncology has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.80, based on 1,233 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Champions Oncology's current PB Ratio of 19.74 is 605% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Champions Oncology and its competitors. For the Biotechnology industry, the median PB Ratio is 2.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Champions Oncology's current PB Ratio is 19.74, which is 13% below median its own 10-year median of 22.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Champions Oncology stock overvalued right now?
Based on GuruFocus' analysis, Champions Oncology (CSBR) is currently considered Fairly Valued. The stock's GF Value™ is $6.62, compared to a current price of $6.08 — trading 8.2% below its estimated fair value. The current PB Ratio is 19.74, which is 13% below median its 10-year median of 22.61 and 605% above the Biotechnology industry median of 2.80. Champions Oncology's overall GF Score™ is 64/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Champions Oncology (CSBR), the current PB Ratio is 19.74 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Champions Oncology (CSBR) Overvalued in 2026?
Based on GuruFocus' analysis, Champions Oncology stock appears to be undervalued.
The current stock price of $6.08 is trading 8.2% below its estimated GF Value™ of $6.62.
GuruFocus considers Champions Oncology to be Fairly Valued.
Key valuation signals for CSBR:
PB Ratio: 19.74 (13% below median its 10-year median of 22.61)
GF Value™: $6.62 vs. price of $6.08 (8.2% below fair value)
Industry Position: 605% above the Biotechnology median (#1153 of 1233)
No single metric tells the full story. See the CSBR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.
64GF Score
Get the complete analysis for CSBR
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSBR has been successfully added to your 
